Phosphodiesterase 4B: Master Regulator of Brain Signaling

• Published in: Cells (Basel, Switzerland) Vol. 9; no. 5; p. 1254
• Main Authors: Tibbo, Amy J, Baillie, George S
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19-05-2020; MDPI
• Subjects: Animals; Brain - enzymology; Brain - physiology; Brain research; Cognition - physiology; Cognitive ability; Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry; Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism; Cyclic nucleotides; cyclic-AMP; Enzyme Activation; Enzymes; Gene expression; Humans; Inflammation; Isoforms; Kinases; Memory; Memory - physiology; Mental disorders; neuroinflammation; Neurological diseases; Nucleotides; PDE4B; Phosphodiesterase; Phosphorylation; Proteins; Review; rolipram; Schizophrenia; Signal Transduction; Therapeutic applications; Transcription factors; PDE4B; cyclic-AMP; rolipram; phosphodiesterase; neuroinflammation
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells9051254

Phosphodiesterases (PDEs) are the only superfamily of enzymes that have the ability to break down cyclic nucleotides and, as such, they have a pivotal role in neurological disease and brain development. PDEs have a modular structure that allows targeting of individual isoforms to discrete brain locations and it is often the location of a PDE that shapes its cellular function. Many of the eleven different families of PDEs have been associated with specific diseases. However, we evaluate the evidence, which suggests the activity from a sub-family of the PDE4 family, namely PDE4B, underpins a range of important functions in the brain that positions the PDE4B enzymes as a therapeutic target for a diverse collection of indications, such as, schizophrenia, neuroinflammation, and cognitive function.